Dako and Cytomation Announce Merger

By HospiMedica staff writers
Posted on 08 Jul 2002

In a move to strengthen their position in the in vitro diagnostic market, Dako A/S (Copenhagen, Denmark) and Cytomation, Inc. (Fort Collins, CO, USA) have combined their complementary competencies and merged their two companies. The new company is called DakoCytomation.

Dako specializes in the identification of cancer markers on tissue samples obtained from biopsies and surgery, while Cytomation is a technology leader in flow cytometry instruments used in advanced cellular analysis. In the last fiscal year, Dako had a 20% increase in sales, while Cytomation reported 35% growth. Their merger results in a company with 1,400 employees, activities in more than 70 countries, and US$175 million in sales. Dako had acquired a minority holding in Cytomation in 20001, which allowed the two companies to develop closer relations and a strategic collaboration.

"We are in a fast-growing market,” said Jes Ostergaard, who is serving as president and CEO of DakoCytomation. "An accurate cancer diagnosis is of high importance to our customers so they can choose the most appropriate treatment for each patient.”

Related Links:
Dako
Cytomation